Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...

Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

Elevated CAR has been associated with adverse outcomes in many conditions, including cancer, sepsis, COVID-19, and cardiovascular diseases. A higher C-reactive protein to albumin ratio (CAR) is ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

Take Charge - I Pledge' campaign engaged 4,350 doctors across six countries, setting a new benchmark in raising COPD ...

In a world where respiratory issues are increasingly common, finding practical solutions can be daunting. Breathe Drops ...